DAOY Xenograft Model Service for Medulloblastoma

The DAOY xenograft model stands as one of the most extensively characterized and widely adopted preclinical platforms for Sonic Hedgehog (SHH) subgroup medulloblastoma, enabling robust evaluation of novel therapeutics in an immunocompromised host environment. At Alfa Cytology, we specialize in constructing high-fidelity DAOY xenograft models using validated cell stocks and standardized protocols, delivering reproducible tumor growth kinetics and comprehensive pharmacodynamic endpoints to support your preclinical drug development pipeline from lead optimization to candidate selection.

Overview of DAOY Xenograft Model for Medulloblastoma

Medulloblastoma is the most common malignant brain tumor in pediatric patients, arising in the cerebellum within the posterior cranial fossa. The DAOY cell line, originally isolated from a desmoplastic medulloblastoma biopsy of a 4-year-old male patient, represents the Sonic Hedgehog (SHH) molecular subgroup and carries a mutated TP53 gene, contributing to its genomic instability and aggressive phenotype. In xenograft applications, DAOY cells demonstrate reliable tumorigenicity in immunodeficient mice, forming serially transplantable tumors via both subcutaneous and orthotopic routes, and have been extensively utilized to evaluate targeted agents including PI3K/Akt/mTOR inhibitors, SHH pathway modulators, and CAR-T cell therapies.

The DAOY xenograft model recapitulates key histopathological features of human medulloblastoma, including small round blue cell morphology and high proliferative index, while offering practical advantages such as moderate growth latency and measurable tumor burden amenable to caliper-based or imaging-based longitudinal monitoring. Researchers frequently employ this model to assess tumor response to radiation, conventional chemotherapeutics, and emerging biologics, leveraging its well-documented molecular profile and consistent engraftment rates to generate translational data supporting downstream clinical development.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting SHH subgroup medulloblastoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving medulloblastoma progression through aberrant SHH signaling, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment.

Figure 1. Cell morphology and cell growth pattern of the medulloblastoma cell lines. a UW402. b UW473. c DAOY. d ONS-76. (Bonfim-Silva, R, et al., 2019)

Cell Line Information: DAOY

The DAOY cell line is a well-established human medulloblastoma line with comprehensive molecular characterization. Its classification within the SHH molecular subgroup and mutated TP53 status makes it unique among available medulloblastoma cell lines and essential for preclinical research targeting this aggressive pediatric brain tumor subtype.

Our Services

Alfa Cytology provides end-to-end DAOY xenograft model services built on authenticated cell stocks, rigorous quality control, and standardized tumor monitoring protocols. Our experienced team manages every phase of model construction---from cell expansion and mouse engraftment to longitudinal tumor measurement and terminal endpoint collection---ensuring consistent, publication-ready data that accelerates your preclinical therapeutic development timeline.

Workflow of DAOY Xenograft Model Construction

Our DAOY xenograft model construction follows a standardized, quality-controlled workflow designed to ensure high engraftment rates, reproducible tumor growth, and reliable pharmacodynamic readouts. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Authentication and Expansion: DAOY cells are retrieved from authenticated master cell banks and expanded under serum-supplemented culture conditions. Cells are validated for mycoplasma negativity, viability (>95%), and typical polygonal morphology prior to harvest.
2. Cell Harvest and Preparation: Exponentially growing DAOY cells are harvested using enzymatic dissociation, washed, and resuspended in a serum-free medium or Matrigel/MEM mixture at a predetermined concentration optimized for engraftment efficiency.
3. Animal Preparation and Implantation: Immunodeficient mice (e.g., Nude or NSG, 6--8 weeks old) are acclimatized and randomized. For subcutaneous models, cells are injected into the flank; for orthotopic models, stereotactic injection into the cerebellar region is performed under anesthesia using a Hamilton syringe with precise posterior fossa coordinates.
4. Tumor Monitoring and Randomization: Tumor establishment is confirmed via palpation or bioluminescence imaging (BLI) within 7--14 days. Mice are randomized into treatment cohorts once tumors reach a predefined baseline volume or signal intensity, ensuring balanced starting parameters across groups.
5. Treatment Administration and Longitudinal Assessment: Test compounds, biologics, or vehicle controls are administered according to the study design. Tumor dimensions or BLI signals are recorded at regular intervals (typically twice weekly), alongside body weight and clinical observation scoring.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and photographed. Tissues are preserved for histopathology (H&E, IHC), molecular analysis (qPCR, Western blot, RNA-seq), and pharmacokinetic profiling. Blood and plasma samples are collected for biomarker and toxicology assessment.

Figure 2: Schematic workflow illustrating the derivation and construction of the DAOY Xenograft Model at Alfa Cytology.

Case Study-DAOY Xenograft Model Development

Alfa Cytology has successfully established and validated the DAOY xenograft model across multiple preclinical studies. In a representative preclinical engagement, DAOY cells were engrafted subcutaneously into immunodeficient mice to evaluate the anti-tumor efficacy of a novel SHH pathway inhibitor. Tumors established consistently within 10--14 days, exhibiting exponential growth kinetics suitable for therapeutic intervention windows. Treatment cohorts demonstrated dose-dependent tumor growth inhibition compared to vehicle controls, with corresponding reductions in proliferative markers and SHH target gene expression observed at terminal analysis. Detailed quantitative data, including tumor growth curves, survival analysis, and biomarker readouts, are available upon request under confidentiality agreements.

Why Choose Alfa Cytology?

Alfa Cytology delivers preclinical DAOY xenograft services grounded in scientific rigor, operational transparency, and client-focused flexibility. Our integrated platform is designed to generate robust, reproducible data that de-risks your therapeutic development decisions.

• Verified Cell Line Integrity: Authenticated DAOY cell stocks with documented STR profiles and regular mycoplasma screening ensure model integrity from the outset.
• High Take Rates and Consistency: Standardized engraftment protocols and experienced surgical teams yield high tumor take rates with minimal inter-animal variability.
• Comprehensive Analytical Support: Flexible study designs accommodate subcutaneous, orthotopic, and patient-derived xenograft (PDX) comparisons to match your translational objectives.
• Tailored Study Designs: Comprehensive endpoint capabilities---including histopathology, molecular profiling, flow cytometry, and imaging---are available under one roof.
• Standardized Protocols: Dedicated project scientists provide real-time data access, milestone reporting, and proactive troubleshooting throughout the study lifecycle.
• Dedicated Project Management: Competitive timelines and transparent pricing structures are tailored to biotech and pharmaceutical clients at every stage of development.

Contact Us

Ready to advance your medulloblastoma therapeutic program with a validated DAOY xenograft model? Contact us today to discuss your study requirements, receive a customized proposal, and partner with a CRO committed to delivering high-quality preclinical data. Please reach out to us today via our inquiry form or email to learn more about our DAOY Xenograft Model services.

For research use only. Not intended for any clinical use.